TD Cowen Upgrades PTC Therapeutics to Buy, Raises Price Target to $90

Benzinga Newsdesk www.benzinga.com Positive 85.7%

Neg 0% Neu 0% Pos 85.7%

TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $75 to $90.